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Abstract: Recent advances in nanotechnology caused a 
growing interest using nanomaterials in medicine to solve 
a number of issues associated with therapeutic agents. 
The fabricated nanomaterials with unique physical and 
chemical properties have been investigated for both diag-
nostic and therapeutic applications. Therapeutic agents 
have been combined with the nanoparticles to minimize 
systemic toxicity, increase their solubility, prolong the 
circulation half-life, reduce their immunogenicity and 
improve their distribution. Multifunctional nanoparti-
cles have shown great promise in targeted imaging and 
therapy. In this review, we summarized the physical 
parameters of nanoparticles for construction of “smart” 
multifunctional nanoparticles and their various surface 
engineering strategies. Outlook and questions for the fur-
ther researches were discussed.
Keywords: drug delivery system; medical applications; 
nanomaterials; nanomedicine; nanoparticles; targeting 
therapy.
Introduction
Nanotechnology and nanobiotechnology have gained 
much momentum in recent years. The term nano technology 
mostly refers to the fabrication of new materials with at 
least one dimension in a size range between 1 and 100 
nanometres (nm), that is one billionth (or 10–9) of a meter. 
It is already used in a variety of products across various 
industries such as agriculture, cosmetics, electronics, tex-
tiles, recycling, energy, chemicals, as well as healthcare. 
Nanobiotechnology is defined by science’s growing ability 
to work at the molecular level, atom by atom, combining 
biological materials and the rules of physics, chemistry, 
and genetics to fabricate synthetic structures such as bio-
sensors, nanosized microchips and even tissue analogs 
for growing skin, bones, muscle, and other organs of the 
body [1, 2]. The development of a wide range of nanoscale 
technologies currently enables new scientific approaches 
in disease diagnosis, treatment, monitoring and preven-
tion. These technological innovations of nanotechnology 
within medicine are referred to as “nanomedicine” by the 
National Institutes of Health in USA [3].
Nanoparticles with ~100  nm have been widely used 
to improve the drug accumulation, internalization and 
therapeutic efficacy. As shown in Figure 1, the physico-
chemical and biological properties of the nanoparticles 
can also be finely adjusted by tailoring their chemical 
properties, sizes, shapes, structures, morphologies, and 
surface properties [4]. The conjugation chemistry strat-
egy of the drug molecule and surface modification is 
very important for drug delivery. Drug molecules may be 
adsorbed or attached covalently to the surface of nanocar-
rier. Besides, the interior core can also entrap drug mole-
cules. The surface coating of nanocarriers with molecules, 
for instance, hydrophilic and/or hydrophobic polymers 
[e.g. polyethylene glycol (PEG) and poly(ε-caprolactone) 
(PCL)] or surface modifications with targeting ligands 
such as antibodies, aptamers, peptides or small molecules 
determine the mechanism of uptake for the nanocarriers 
by the cells. Nanoparticles can be modified by active and 
passive targeting to enhance the concentration of the drug 
molecule inside the specific area. Once the drug loaded 
nanocarriers reach the diseased tissue, the therapeutic 
agent is released through changes in physiological envi-
ronment such as temperature, pH, osmolarity, or via an 
enzymatic activity [5].
Delivering of therapeutic compound to the target site 
is a major problem in the treatment of many diseases. A 
conventional application of drugs may have limited effec-
tiveness, poor biodistribution and lack of selectivity [6]. 
It has been established that nanocarriers can become 
concentrated preferentially in tumors or at inflammatory 
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sites, and this is due to antigen sampling by virtue of the 
enhanced permeability and retention (EPR) effect of the 
vasculature [7]. The current treatment options for most 
solid tumors are surgical intervention combined with 
chemotherapy or radiation therapy. However, today’s 
therapy in its very general and systemic application form 
damages healthy tissues and causes unwarranted toxicity 
to the patient [8, 9]. In recent years, nanoparticle based 
delivery systems have been exploited in various medical 
applications. Their attractive features are that they are 
made from biocompatible, well-characterized and easily 
functionalized materials [10]. On the basis of these materi-
als’ properties, nanomaterials exhibit a highly differential 
targeting and uptake efficiency in a cell- or tissue-specific 
manner. Furthermore, the drug molecule on the nanocar-
rier is protected from harsh conditions before it can reach 
the target. In contrast to conventional drug delivery, using 
nanomaterials a prolonged and controlled drug release 
can be achieved [11, 12]. Thus, nanomedicine represents 
an innovative field with enormous potential for treatment 
by combination of smart nanoparticles with small mol-
ecules carrying a wide range of functions.
Liposomes, polymeric nanoparticles, dendrimers, 
metal nanoparticles, and quantum dots are versatile mol-
ecules with a variety of biomedical uses, such as diag-
nostic assays [13, 14], radiotherapy enhancement [15, 16], 
as well as drug and gene delivery [17, 18]. Liposomes are 
artificially prepared vesicles composed of lipid bilayers. 
They are biocompatible and their size can be varied in 
broad ranges (50–500 nm). Both hydrophobic and hydro-
philic drugs can be encapsulated in the hydrophobic 
lipid bilayer and hydrophilic aqueous core, respectively 
[19]. An alternative approach to liposome is the use of 
niosomes which are composed mainly of non-ionic sur-
factants [20]. Polymeric nanoparticles made of natural 
polymers (e.g. chitosan, collagen) and synthetic polymers 
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Figure 1: Design of nanoparticles for drug delivery.
Multifunctional nanoparticles can be generated from the different materials composition with different properties and functionalities. 
Various strategies are used to combine therapeutic agents and imaging probes with the particles.
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[e.g. poly(lactide-coglycolide) (PLGA) and (PCL)] are col-
loidal solid platforms for controlled and sustained release 
of drug molecules and gene delivery. Natural polymers 
are less toxic and more biodegradable than synthetic 
polymers. The majority of these compounds are synthe-
sized through a spontaneous self-assembly process using 
block polymers of two or more polymeric chains with dif-
ferent hydrophilicity [21]. Dendrimers are synthesized 
from branched monomers by stepwise a repetitive reac-
tion sequence and it is possible to control of their struc-
tural and chemical properties, including size, shape and 
number of branches. Poly(amidoamine) (PAMAM) and 
poly-L-lysine are largely used dendrimers in drug and 
gene delivery. Low polydispersity and biocompatibility 
are the main problems using these nanoparticles as a tool 
in nanomedicine [22]. Semiconductor quantum dots are 
utilized as fluorescent probes for imaging and labeling of 
the molecules due to their unique photophysical charac-
teristics such as broad excitation and tunable emission. 
Nevertheless, the main components of the quantum dots 
are hazardous heavy metals such as cadmium and sele-
nium, which are highly toxic in living organisms. The 
heavy metal core can be coated with shell and a further 
surface coating can be carried out to make quantum dot 
more biocompatible [23]. Researchers are interested to 
study tracking of these nanoparticles and to investigate 
their physical and biological properties for their cellular 
uptake and delivery.
Physical properties and  applications 
of nanoparticle based drug carriers
Size and shape
The physicochemical properties of nanoparticles, size, 
shape, and surface chemistry play a critical role in deter-
mining tissue penetration, cellular delivery, and thera-
peutic efficacy. Nanoparticles with varying size and shape 
are taken up to the cells at different rates. Cell membrane 
is composed of lipids, carbohydrates and proteins that 
mediate cellular functions. The nanoparticle surface 
can interact with these molecules and may activate the 
cell’s uptake mechanisms. Nanoparticle cell interac-
tions can be remarkably different from that of small or 
large sized particles at nanoscale [24]. As nanoparticles 
with a smaller size have larger surface areas available to 
adhere and interact with cell membranes, the decrease 
of nanoparticle size may lead to an increase in mobility 
and interaction with cell membranes, which can result in 
enhanced cellular uptake of nanoparticles [25]. Besides, 
because of their small size, nanoparticles are often not 
recognized as a foreign agent by macrophages and con-
sequently do not enter macrophages through membrane 
pores to be led to the digestion apparatus for such micro-
particles, the reticuloendothelial system [26]. Donkor and 
Tang showed that, the cellular and nuclear internalization 
of 30 nm sized single-walled carbon nanotubes (SWCNT) 
was higher than 50 nm SWCNT [27]. In a subsequent study, 
Jiang et al. reported that relatively small sizes of 2, 4 and 
6  nm core gold nanoparticles (AuNP) were sufficient to 
induce dramatic changes in nanoparticle internalization 
efficiency and mechanism [28].
The shape of nanoparticles also plays a direct role for 
their function in biological systems [29]. Li and coworkers 
investigated the influence of nanoparticle shape on the 
cellular uptake. To clarify its on cellular uptake of the nan-
oparticles, sphere, rod, cube, and disk shaped polymer-
coated nanoparticles were compared. Based on a detailed 
free energy analysis, the effect of the nanoparticle shape 
was found to be mainly induced by the different mem-
brane bending energies during endocytosis. The spherical 
nanoparticles needed to overcome a minimal membrane 
bending energy barrier, compared with non-spherical par-
ticles. The spherical nanoparticles thus demonstrated the 
fastest internalization rate, followed by cubic-, then rod- 
and disk-like nanoparticles [30].
Even though nanoparticles show a certain size and 
shape after synthesis, they might induce aggregation into 
larger clumps during the in vitro and in vivo applications. 
The formation of these aggregates complicates the inter-
pretation of the results [31]. Besides, although both size 
and shape are essential features, surface charge and func-
tionality are also significant for the interaction of nano-
particles with the physiological system.
Surface chemistry
In addition to their size and shape, the surface chemistry 
of nanoparticles is an important factor for their interaction 
with the biological environment. Nanoparticles should 
ideally have a hydrophilic surface to escape macrophage 
capture [32]. Generally, that can be achieved by coating 
the surface of nanoparticles with a hydrophilic polymer 
such as PEG, which has favorable inherent physicochemi-
cal properties and is biocompatible (e.g. it possesses high 
flexibility, but a low toxicity and immunogenicity). For 
this purpose, nanoparticles can also be fabricated from 
block copolymers with hydrophilic and hydrophobic parts 
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[33, 34]. A surface modification of nanoparticles with PEG 
was found to reduce nanoparticle accumulation in off-tar-
get organs such as liver and spleen. PEG-coated nanopar-
ticles have a high solubility in a number of solvents and 
exhibit a reduced adsorption of blood proteins, leading to 
prolonged circulation half-life compared to non-PEGylated 
nanoparticles [35–37]. In this way, it reduces the aggrega-
tion. PEG chains can be functionalized with alcohols, 
carboxylic acids amines and thiols to conjugate small mol-
ecules or targeting ligands. Yoon et al. demonstrated that 
tumor-targeting ability of hyaluronic acid nanoparticles 
(HANPs) could be optimized by chemical conjugation of 
amine-functionalized PEG, which might help escaping the 
unintended accumulation in liver [38].
The charge of nanoparticle’s surface is commonly char-
acterized using the zeta potential, which variably reflects 
the electrostatic potential of particles and is influenced by 
the composition of the particles as well as by the medium in 
which the nanoparticles are suspended [3]. Particles with a 
zeta potential more positive than +30 mV or more negative 
than −30 mV are normally considered to be physically stable 
[39, 40]. The negative membrane of cells interact differently 
with positively/negatively charged nanoparticles, whereby 
positively charged nanoparticles are generally known to 
be more easily internalized than neutral and negatively 
charged nanoparticles [41, 42]. Remarkably, some nanopar-
ticles such as polymeric nanocomplexes and AuNP, which 
have the same size range, but different surface charges 
yielded marked discrepancies in both distribution and 
uptake efficiency. The particles also showed different levels 
of toxicity depending on their surface charges [43–46].
Targeting ligands
Nanoparticle surfaces are often bioconjugated with small 
molecules and/or targeting ligands to enable both in vitro 
and in vivo cell specific targeting [47]. Proteins and pep-
tides, carbohydrates, vitamins, aptamers, antibodies, and 
antibody fragments are the mostly used molecules that 
bind specifically to an overexpressed target on the cell 
surface [48]. Immunogenicity, stability, and difficulties 
in site-specific conjugations with nanoparticles are the 
major obstacles in targeting ligands. Monoclonal antibod-
ies (mAbs) are widely preferred targeting ligands because 
of their availability to research and their high affinity and 
specificity for molecular targets [49, 50]. Several mAbs 
have been used in clinics for cancer therapy, such as 
bevacizumab (against colorectal cancer) and trastuzumab 
(against breast cancer) [51]. However, they are large, 
complex molecules and may cause immunogenicity.
Aptamers are small synthetic nucleic acid oligom-
ers that can bind to targets with high sensitivity and 
high specificity. Aptamers are selected through an in 
vitro process called systematic evolution of ligands by 
exponential enrichment (SELEX) to be most specific 
for a particular target [52]. They have potential advan-
tages as targeting ligands. Aptamers can be synthesized 
with a specific functional moiety, such as a carboxylate, 
amino or sulfhydryl at only one end of the nucleic acid 
sequence of the aptamer. They are small in size and 
non-immunogenic [50, 53]. Peptides are an attractive 
alternative as targeting molecule due to several advan-
tages, including a smaller size, a lower immunogenicity, 
a higher tissue penetration capability, a higher stabil-
ity and a relatively easy production process. Phage-
displayed peptide libraries are a valuable screening 
resource for identification of the peptides that target a 
specific receptor [54, 55]. The most widely used peptide 
in targeted delivery is the integrin targeted arginine-
glycine-aspartic acid (RGD) peptide. This peptide has 
been extensively studied by combining various nano-
particles [56]. A promising approach for overcoming the 
barrier of the cell membrane in drug delivery are cell 
penetrating peptides (CPPs). Arginine rich CPPs such 
as transactivator of transcription (TAT), penetratin and 
polyarginine are often used for intracellular delivery of 
the cargo conjugates [57]. It has been hypothesized that 
the positively charged CPPs provide a strong electro-
static interaction with anionic species presented at the 
extracellular surface of cell membranes, including lipid 
head groups, proteins such as nucleolin, and proteogly-
cans like heparin sulfate [58, 59].
Passive and active targeting
Targeting of the nanoparticles is performed via two differ-
ent strategies: passive and active targeting, as schemati-
cally shown in Figure 2. Nanoparticles can enhance the 
intracellular concentration of the drugs in cancer cells 
while avoiding unwarranted toxicity towards healthy 
cells. Malignant tumors release angiogenic growth factor 
proteins that stimulate new blood vessels or demand 
rerouting of existing vessels to supply them oxygen and 
nutrients [61, 62]. Tumor tissue is characterized by highly 
disorganized vascular architecture, irregular blood flow, 
reduced lymphatic drainage, and vessels are leaky [63, 64]. 
Because of the reduced lymphatic drainage, the permeat-
ing nanocarriers are not removed efficiently, and thus are 
retained in the tumor tissue [65]. These features provide 
an EPR effect, which constitutes an important mechanism 
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Figure 2: Active and passive targeting of drug loaded nanoparticles.
(Reprinted with permission from Ref. [60], Copyright 2014 BioMed Central.)
for the passive targeting and the selective accumulation 
of nanoparticles in the tumor and also in its surrounding 
tissue [66]. Gabizon et al. showed that a PEGylated liposo-
mal doxorubicin (Dox) formulation had a long circulation 
time in plasma, enhanced accumulation in murine tumors 
and a high therapeutic activity over free (unencapsulated) 
Dox [67].
The objective of the active targeting strategy is to over-
come specificity limitations of drug conjugate by using 
targeting moieties. Nanoparticles are typically conjugated 
with targeting ligands that was described in the previous 
section, thereby allowing preferential accumulation of 
the drug within selected tissues or intracellular organelles 
[68]. Fabricated nanoparticles may enter the cells via dif-
ferent endocytic pathways such as receptor-mediated 
endocytosis depending on their size, shape, and surface 
properties (Figure 3).
Drug loading and release
High drug loading capacity is essential for a successful 
drug delivery system. The surface chemistry of the nano-
particles and the properties of the drug as well as some 
environmental factors such as release conditions have a 
strong influence on both drug loading and release. The 
loading of drug molecules into the nanoparticles can be 
performed by two methods. Within the incorporation 
method, the drug should be incorporated at the time 
of nanoparticle formation. In the adsorption/absorp-
tion method, the nanocarrier should be incubated with 
the concentrated drug solution [69]. Drug loading and 
entrapment efficiency is determined by the properties of 
the drug and the carrier molecule. Biomolecules, drugs 
or proteins show the greatest loading efficiency when 
they are loaded at or near their isoelectric point (pI), 
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comprising a minimal solubility and a maximal absorp-
tion. Prior studies showed, that the use of ionic inter-
actions between the drug and the matrix material can 
be an effective way to increase drug loading for small 
molecules [70, 71].
Summarizing, while designing a nanoparticle based 
drug delivery system, subsequent biodegradation and 
drug release should be considered. Loading the drug 
molecules inside or on the surface of nanoparticle carrier 
allows controlled release of the drug. This method bears 
many advantages such as improving biodistribution, 
reducing unwarranted side toxicity for healthy tissue and 
protecting the drug from physiological degradation com-
pared to conventional free drugs administration [49]. Des-
orption of the drugs, drug diffusion from the nanoparticle 
matrix, matrix erosion or degradation of nanoparticles 
determine the release rate of the drug [3, 69].
Conclusions
Utilization of nanoparticles as drug carriers offer promis-
ing improvements in drug delivery. The loading of drug 
molecules into or on top of the nanocarriers can improve 
the pharmacokinetic properties of the drug and can 
protect the drug against early degradation enabling tar-
geted and controlled drug release. Thus, accumulation 
of the drugs in targeted size can be increased and in this 
way occurrence of undesired drug effects can be pre-
vented in healthy tissues. Furthermore, multifunctional 
nanoparticles with simultaneously useful capabilities 
such as targeting and imaging contrast enhancement 
can be synthesized. These nanoparticles combine both 
diagnostic and therapeutic features within a single for-
mulation and therefore are denoted as “theranostic” 
agents [72–74].
Figure 3: Schematic representation of the cytosolic delivery of drug loaded nanoparticles via receptor mediated endocytosis.
The nanoparticles are engulfed in a vesicle, called early endosome, after receptor mediated cell association with nanoparticles. Endosomal 
escape of the nanoparticles leads to the cytosolic release of the encapsulated drug molecule.
(Modified reproduction with permission from Ref. [56], copyright 2015 American Chemical Society.)
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Despite the fact that there are several nanoparticle 
based drug delivery systems, being developed or being 
currently under preclinical and/or clinical evaluation, 
still only a few such nano-drugs are in use on the market 
[75]. This is due to the fact that some problems in clinical 
usage encountered such as low drug loading capacity and 
a low circulation half-life, leading to low release and diag-
nostic features. Furthermore, the still relatively low physi-
cal stability and scale up problems bring along limitations 
for therapeutic applications of nanoparticle based drug 
delivery systems. Besides, the studies show that ultrafine 
particles (UFPs; diameter <100 nm) are more toxic and 
induce more severe inflammation than larger particles in 
their effects [76]. Within the field of nanotoxicology, safe 
nanomaterials will be designed and new methods and 
techniques for analyzing these nanostructures in in vitro 
test platforms will be developed.
The greater part of the fabricated drug delivery 
systems work well in vitro, however many systems fail in 
in vivo testing because of excessive accumulation and tox-
icity in the kidneys and liver [77]. In the last decade, three-
dimensional (3D) cell culture systems have drawn great 
attention because they often offer levels of cell differentia-
tion and tissue organization not observed in conventional 
two-dimensional (2D) culture systems [78]. In recent 
years “organ-on-a-chip” systems are useful as an in vitro 
approach to test drugs and nanoparticles by mimicking 
the specific physiological environment found in certain 
organs. But both these technologies are relatively new and 
require further validation to predict clinical responses in 
human.
Consequently, smart multifunctional nanoparticles 
will be the most promising candidates as drug carriers in 
nanomedicine after identification on relevant targets and 
production of novel molecules. This molecules will enable 
the development of personalized drug delivery systems by 
improving the life quality and duration of the patients.
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